Can switching breast cancer drugs improve outcomes? new study investigates
NCT ID NCT06928818
First seen May 02, 2026 · Last updated May 21, 2026 · Updated 2 times
Summary
This study observes 100 people in Korea with advanced HER2-positive breast cancer who will receive the drug T-DM1 immediately after stopping T-DXd. The goal is to see how long the cancer stays under control with this treatment sequence. Researchers will track tumor scans and survival rates, but this is an observational study, not a test of a new drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF BREAST are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Hospital
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.